SMS Pharmaceuticals growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+13.3%+10.4%+35.9%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+23.2%+19.2%+114.0%
+25.5%+23.0%+280.3%
+47.5%+38.8%+805.8%
+36.6%+38.5%+809.6%
+18.2%+11.5%+17.6%
+22.9%+19.3%+16.5%
−27.5%+63.0%+123.3%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

SMSPHARMA₹475.45

SMS Pharmaceuticals Limited

· Pharma & Health
₹ CrorePeersINDSWFTLABSOLARADCALUNICHEMLABGUFICBIORPGLIFEHIKALGUJTHEMMcap ₹4,453 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—+35.9+10.4+13.3—
EBITDA Growth—+114.0+19.2+23.2—
EBIT Growth—+280.3+23.0+25.5—
Net Income Growth—+805.8+38.8+47.5—
EPS Growth—+809.6+38.5+36.6—
Total Assets Growth—+17.6+11.5+18.2—
Total Equity Growth—+16.5+19.3+22.9—
Cash from Operations Growth—+123.3+63.0-27.5—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.